Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in HLA Sensitized Kidney Transplant Recipients.
The efficacy and safety of belatacept when converted from calcineurin inhibitors (CNI) in HLA-sensitized kidney transplant recipients has not been established. The study included 108 kidney transplant recipients converted from CNI to belatacept between 7/1/12 to 9/30/17. Rejection-free, patient, and graft survival over 5 years follow-up were compared between HLA-sensitized (HS) and non-HLA sensitized (non-HS) recipients using the Kaplan-Meier product-limit method. The eGFR slope post conversion was compared using linear mixed effects models. There were 29 HS and 79 non-HS recipients included. Rejections after conversion were mostly cell-mediated. There was no difference in rejection-free survival (log-rank p=0.30; at 5 years, HS: 82%; non-HS: 84.6%); however, rejection-free survival was lower among HS recipients converted within the first year post transplant compared to non-HS recipients (log-rank p=0.03; at 5 years, HS: 55.6%; non-HS: 75.0%) . There was no difference in patient survival (log-rank p=0.75; at 5 years, HS: 85.7%, non-HS: 83.7%;) or graft survival (log-rank p=0.17; at 5 years, HS: 78.5%, non-HS: 89.8%) in the two groups. On average, eGFR slope improved post conversion in non-HS [0.28 ml/min/1.73 m/year (0.03 to 0.53)] but declined in HS recipients [-0.44ml/min/1.73 m/year (-0.85 to -0.03)]. There was no difference in rejection-free, patient, or graft survival after conversion to belatacept over 5 years among HS and non-HS recipients. However, rejection-free survival was lower in HS recipients converted to belatacept within the first year post transplant. Conversion from CNI to belatacept should be done cautiously in high immunologic risk patients.